The Medical Letter on Drugs and Therapeutics
Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved another solution of the aminoglycoside antibiotic tobramycin (Bethkis – Chiesi/Cornerstone) for oral inhalation via a nebulizer for management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

INHALED ANTIBIOTICS FOR CF — Inhaled antibiotics, which can achieve high concentrations in the lung with minimal systemic side effects, are probably the most effective therapy available for chronic P. aeruginosa infection in patients with CF.1 Tobramycin and aztreonam (Cayston) are the only 2 antibiotics that are FDA-approved for such use. Bethkis delivers the same dose of tobramycin as an older formulation (Tobi, and generics), but in a more concentrated solution. An orally inhaled dry powder formulation of tobramycin (Tobi Podhaler) was approved by the FDA in 2013. It is more convenient to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis
Article code: 1445c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian